Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYC-30937 in active ulcerative colitis
NCT02818543Phase 1Completed
- Sponsor
- Lycera
- Start
- Mar 2016
- Primary completion
- Jun 2016
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of parimifasor in ulcerative colitis (UC) (2 cohorts), sponsored by Lycera. Primary endpoints: Maximum observed plasma concentration up to 48 hours, Time to maximum observed plasma concentration up to 48 hours and 1 more. Started Mar 2016; status: completed.
02
Drugs
parimifasor
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02818543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02818543.